TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02775435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Carboplatin dose should not to exceed 900 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion Carboplatin dose should not to exceed 900 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline placebo for pembrolizumab
Description: IV infusion
Study: NCT01872611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as placebo comparator
Study: NCT02842723

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protontherapy
Description: 59,5 Gy (1,7 Gy daily, 5 fractions per week).
Study: NCT01710670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brivaracetam Placebo
Description: In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol Placebo
Description: In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
Study: NCT03480022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: daily sc injection of liraglutide with final dose of 3mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liraglutide Pen Injector
Description: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
Study: NCT01346644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Powder infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Powder infant formula
Study: NCT04196972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive ECHO telementoring intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting List
Description: Placed on wait-list
Study: NCT02629484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focused cardiac ultrasound
Description: focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
Study: NCT01583920

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: focal salvage HDR prostate brachytherapy
Description: Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
Study: NCT03701321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT02005653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Experimental
Study: NCT01044277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione supplementation
Description: 500 mg, two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gluthathione peroxidases
Description: 125 mg, two times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times daily
Study: NCT02645305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived stem cells
Description: Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
Study: NCT03370835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Non-cardioselective beta-blocker
Study: NCT01872611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study: NCT03370835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Non-cardioselective beta-blocker
Study: NCT01872611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study: NCT00589472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study: NCT04308447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AbleLite
Description: The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
Study: NCT00589472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical prostatectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03701321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03183011

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Cardiac MRI
Study: NCT01556737

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High daidzein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High daidzein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High genistein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High genistein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones
Study: NCT02106910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
Study: NCT01664715

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 150 Min/Week
Description: Performs 150 min/wk of planned moderate intensity aerobic exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 225 Min/Week
Description: Performs 225 min/wk of planned moderate intensity aerobic exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 300 Min/Week
Description: Performs 300 min/wk of planned moderate intensity aerobic exercise.
Study: NCT02240875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 1 x 10^10 vp
Description: Low dose cAd3-EBO Z
Study: NCT02712255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
Study: NCT02405754

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study: NCT03300960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Provera 10 mg.
Description: One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix (GnRH antagonist)
Description: One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
Study: NCT03312543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Mask
Description: A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Mask
Description: A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
Study: NCT03126370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF with a boosted protease inhibitor
Description: Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment
Study: NCT01472185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine tablets administered orally twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ranolazine administered orally twice daily.
Study: NCT03126370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF with a boosted protease inhibitor
Description: Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF with a boosted protease inhibitor and LDV/SOF
Description: After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment
Study: NCT04014309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive and survivorship care program
Description: Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT03865134

Intervention type: DIAGNOSTIC_TEST
Intervention: Snellen Test
Description: Visual acuity measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Snellen Test
Description: Visual acuity measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Snellen Test
Description: Visual acuity measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer
Description: Refraction measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer
Description: Refraction measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer
Description: Refraction measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Titmus Stereo Fly Test
Description: Stereopsis measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Titmus Stereo Fly Test
Description: Stereopsis measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Titmus Stereo Fly Test
Description: Stereopsis measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Kohlerans Tomography
Description: Retinal development measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Kohlerans Tomography
Description: Retinal development measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Kohlerans Tomography
Description: Retinal development measurement

Intervention type: BEHAVIORAL
Intervention: Investigation of Visual Motor Integration
Description: Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.

Intervention type: BEHAVIORAL
Intervention: Investigation of Visual Motor Integration
Description: Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.

Intervention type: BEHAVIORAL
Intervention: Investigation of Visual Motor Integration
Description: Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.

Intervention type: BEHAVIORAL
Intervention: Peabody Developmental Motor Scales - II
Description: Evaluation of motor development

Intervention type: BEHAVIORAL
Intervention: Peabody Developmental Motor Scales - II
Description: Evaluation of motor development
Study: NCT01472185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match ranolazine administered orally twice daily.
Study: NCT03865134

Intervention type: BEHAVIORAL
Intervention: Peabody Developmental Motor Scales - II
Description: Evaluation of motor development

Intervention type: BEHAVIORAL
Intervention: World Health Organization Quality of Life - BREF
Description: Assesment of quality of life
Study: NCT01472185

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study: NCT03865134

Intervention type: BEHAVIORAL
Intervention: World Health Organization Quality of Life - BREF
Description: Assesment of quality of life
Study: NCT02240875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 1 x 10^10 vp
Description: Low dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z
Study: NCT02240875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 5 x 10^10 vp
Description: High dose cAd3-EBO Z
Study: NCT03865134

Intervention type: BEHAVIORAL
Intervention: State - Trait Anxiety Inventory
Description: Assesment of anxiety

Intervention type: BEHAVIORAL
Intervention: State - Trait Anxiety Inventory
Description: Assesment of anxiety

Intervention type: BEHAVIORAL
Intervention: State - Trait Anxiety Inventory
Description: Assesment of anxiety